淋巴瘤的分期与疗效评估：卢加诺分类法及氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）作用的简要综述
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.
作者信息
Yoo Kwai Han
机构信息
Division of Hematology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.
出版信息
Blood Res. 2022 Apr 30;57(S1):75-78. doi: 10.5045/br.2022.2022055.
Abstract
The accurate assessment of initial disease status and therapeutic responses is critical to the optimal management of patients with lymphoma. Currently, staging and treatment response evaluation for lymphoma has been standardized into the Lugano classification. Lugano classification incorporates positron emission tomography (PET) into the existing response criteria, and response assessment using FDG-PET/CT has been proven to predict the prognosis in various lymphoma subtypes effectively. We will briefly review the current staging and response evaluation system and explore the role of functional imaging in the field of lymphoma.
摘要
准确评估初始疾病状态和治疗反应对于淋巴瘤患者的最佳管理至关重要。目前，淋巴瘤的分期和治疗反应评估已标准化为卢加诺分类。卢加诺分类将正电子发射断层扫描（PET）纳入现有的反应标准，并且已证明使用氟脱氧葡萄糖PET/CT进行反应评估可有效预测各种淋巴瘤亚型的预后。我们将简要回顾当前的分期和反应评估系统，并探讨功能成像在淋巴瘤领域中的作用。
相似文献
1
Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT.
Blood Res. 2022 Apr 30;57(S1):75-78. doi: 10.5045/br.2022.2022055.
2
F-FDG PET/CT in the clinical management of patients with lymphoma.
Rev Esp Med Nucl Imagen Mol. 2017 Sep-Oct;36(5):312-321. doi: 10.1016/j.remn.2017.03.004. Epub 2017 May 5.
3
Staging and response assessment in lymphomas: the new Lugano classification.
Chin Clin Oncol. 2015 Mar;4(1):5. doi: 10.3978/j.issn.2304-3865.2014.11.03.
4
Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Cancer. 2021 Oct 15;127(20):3727-3741. doi: 10.1002/cncr.33772. Epub 2021 Jul 19.
5
PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up.
Semin Nucl Med. 2018 Jan;48(1):37-49. doi: 10.1053/j.semnuclmed.2017.09.004. Epub 2017 Nov 6.
6
Imaging for diagnosis, staging and response assessment of Hodgkin lymphoma and non-Hodgkin lymphoma.
Pediatr Radiol. 2019 Oct;49(11):1545-1564. doi: 10.1007/s00247-019-04529-8. Epub 2019 Oct 16.
7
A comparison of clinical staging using the Lugano versus Ann Arbor classifications in Japanese patients with Hodgkin lymphoma.
Asia Pac J Clin Oncol. 2020 Jun;16(3):108-114. doi: 10.1111/ajco.13248. Epub 2019 Dec 4.
8
Overview and recent advances in PET/CT imaging in lymphoma and multiple myeloma.
Eur J Radiol. 2021 Aug;141:109793. doi: 10.1016/j.ejrad.2021.109793. Epub 2021 May 27.
9
[Update on the use of FDG-PET/CT in malignant lymphoma].
Rinsho Ketsueki. 2016;57(10):2008-2012. doi: 10.11406/rinketsu.57.2008.
10
[Values of Different Evaluation Criteria of Interim F-FDG PET/CT Scan for Prediction of Prognosis in Patients with DLBCL].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Apr;25(2):431-437. doi: 10.7534/j.issn.1009-2137.2017.02.022.
引用本文的文献
1
Systematic literature review to identify prognostic factors of efficacy and safety outcomes of chimeric antigen receptor T-Cell therapies in diffuse large B-Cell lymphoma.
J Cancer Res Clin Oncol. 2025 Jul 7;151(7):203. doi: 10.1007/s00432-025-06249-z.
2
The Role of Platelet to Lymphocyte Ratio (PLR) in Predicting Early Treatment Response in Diffuse Large B Cell Lymphoma.
Indian J Hematol Blood Transfus. 2025 Apr;41(2):333-339. doi: 10.1007/s12288-024-01839-2. Epub 2024 Aug 12.
3
A Rare Head and Neck Tumor: Making Simple Things Complicated.
Cureus. 2024 Dec 29;16(12):e76576. doi: 10.7759/cureus.76576. eCollection 2024 Dec.
4
Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients.
World J Radiol. 2025 Jan 28;17(1):99207. doi: 10.4329/wjr.v17.i1.99207.
5
The influence of marital status at diagnosis on survival of adult patients with mantle cell lymphoma.
J Cancer Res Clin Oncol. 2024 Mar 11;150(3):120. doi: 10.1007/s00432-024-05647-z.
6
Clinical significance of bone marrow involvement by immunoglobulin gene rearrangement in diffuse large B-cell lymphoma: a multicenter retrospective study.
Front Oncol. 2024 Feb 12;14:1363385. doi: 10.3389/fonc.2024.1363385. eCollection 2024.
7
Geriatric risk model for older patients with diffuse large B-cell lymphoma (GERIAD): a prospective multicenter cohort study.
Korean J Intern Med. 2024 May;39(3):501-512. doi: 10.3904/kjim.2023.265. Epub 2024 Jan 30.
8
Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma.
Cancer Imaging. 2023 Jan 24;23(1):11. doi: 10.1186/s40644-023-00520-7.
9
Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
AJR Am J Roentgenol. 2023 Apr;220(4):590-603. doi: 10.2214/AJR.22.28453. Epub 2022 Oct 5.
本文引用的文献
1
Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).
PET Clin. 2022 Jan;17(1):145-174. doi: 10.1016/j.cpet.2021.09.006.
2
Current Role of Functional Imaging in the Management of Lymphoma.
Curr Oncol Rep. 2021 Nov 4;23(12):144. doi: 10.1007/s11912-021-01127-6.
3
PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.
Br J Radiol. 2021 Nov 1;94(1127):20210576. doi: 10.1259/bjr.20210576. Epub 2021 Sep 14.
4
The optimal use of PET/CT in the management of lymphoma patients.
Br J Radiol. 2021 Nov 1;94(1127):20210470. doi: 10.1259/bjr.20210470. Epub 2021 Aug 20.
5
Applications of artificial intelligence in oncologic F-FDG PET/CT imaging: a systematic review.
Ann Transl Med. 2021 May;9(9):823. doi: 10.21037/atm-20-6162.
6
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018.
Cancer Res Treat. 2021 Apr;53(2):301-315. doi: 10.4143/crt.2021.291. Epub 2021 Mar 17.
7
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Am J Hematol. 2021 May 1;96(5):617-629. doi: 10.1002/ajh.26151. Epub 2021 Mar 19.
8
Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3198-3220. doi: 10.1007/s00259-021-05233-2. Epub 2021 Feb 18.
9
The role of PET in the first-line treatment of the most common subtypes of non-Hodgkin lymphoma.
Lancet Haematol. 2021 Jan;8(1):e80-e93. doi: 10.1016/S2352-3026(20)30365-3. Epub 2020 Dec 22.
10
Artificial intelligence applications for oncological positron emission tomography imaging.
Eur J Radiol. 2021 Jan;134:109448. doi: 10.1016/j.ejrad.2020.109448. Epub 2020 Nov 30.
Zotero 插件